FrancophonIA/ELRC3.0 huggingface dataset:
English: Considering the data on low immunogenicity available today, the CHMP identified a potential risk associated to continued vaccination with Hexavac, in terms of long-term protection against Hepatitis B infection and subject boostability post priming with Hexavac.
Slovenian: Ob upoštevanju podatkov o nizki imunogenosti, ki so danes na voljo, je Odbor za zdravila za uporabo v humani medicini ugotovil potencialno tveganje, povezano s ponavljajočim se cepljenjem s Hexavacom v smislu dolgotrajne zaščite pred okužbo s hepatitisom B in obnovitvenim cepljenjem posameznika po primarnem cepljenju s Hexavacom.
English: Unpredictable variances to the immunogenicity of the HepB component were investigated by the MAH.
Slovenian: Nepredvidljive razlike v imunogenosti HepB sestavine je preučeval imetnik dovoljenja za promet z zdravilom.
English: • The CHMP identified that the decreased immunogeniticy of the HepB component released by the MAH seems to be due to variability in the production process for this component.
Slovenian: • Odbor za zdravila za uporabo v humani medicini je ugotovil, da je zmanjšana imunogenost HepB sestavine, ki jo je na tržišče dal imetnik dovoljenja za promet z zdravilom, posledica razlik v
English: Most of the patients received treatment for up to six months: 789 received it for at least six months, and 190 received it for a year.
Slovenian: Večina bolnikov je prejemala zdravilo v trajanju do največ šest mesecev, 789 bolnikov je prejemalo zdravilo najmanj šest mesecev, 190 bolnikov pa je prejemalo zdravilo eno leto.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Trazec to Novartis Europharm Limited on 3 April 2001.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Trazec, veljavno po vsej Evropski uniji, odobrila družbi Novartis Europharm Limited dne 3. aprila 2001.
English: Its use is not recommended in pregnancy or while breast feeding.
Slovenian: Uporaba zdravila ni priporočljiva med nosečnostjo ali dojenjem.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
Slovenian: Pojasnjuje, kako je odbor za zdravila za uporabo v humani medicini (CHMP) ocenil opravljene študije, na podlagi katerih je oblikoval priporočila glede uporabe zdravila.
English: Trazec is given within one to 30 minutes before breakfast, lunch and dinner and the dose is adjusted to give the best control.
Slovenian: Zdravilo Trazec se zaužije minuto do 30 minut pred zajtrkom, kosilom in večerjo, pri čemer se odmerek prilagodi tako, da omogoča najboljši nadzor.
English: The Committee recommended that Trazec be given marketing authorisation.
Slovenian: Odbor je zato priporočil, da se za zdravilo Trazec odobri dovoljenje za promet.
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part
Slovenian: Če želite več informacij, ki temeljijo na priporočilih CHMP, preberite znanstveno razpravo (ki je prav tako del EPAR).
English: The recommended starting dose is 60 mg three times a day before meals.
Slovenian: Priporočeni začetni odmerek je 60 mg trikrat dnevno pred obroki.
English: What is the risk associated with Trazec?
Slovenian: Kakšna tveganja so povezana z zdravilom Trazec?
English: If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Če potrebujete več informacij o vašem zdravstvenem stanju ali zdravljenju, preberite Navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujete s svojim zdravnikom ali s farmacevtom.
English: A total of 2,122 patients received Trazec in all trials combined.
Slovenian: V vseh preizkušanjih skupaj je zdravilo Trazec prejemalo 2122 bolnikov.
English: It is available as pink, round (60 mg), yellow, oval (120 mg) and red, oval (180 mg) tablets.
Slovenian: Na voljo je v obliki rožnate okrogle tablete (60 mg), rumene ovalne tablete (120 mg) ali rdeče ovalne tablete (180 mg).
English: What benefit has Trazec shown during the studies?
Slovenian: Kakšne koristi je zdravilo Trazec izkazalo med raziskavami?
English: A doctor should regularly test the patient's blood glucose to find the lowest effective dose.
Slovenian: Zdravnik mora redno preverjati koncentracijo bolnikove glukoze v krvi, da določi najmanjši učinkoviti odmerek.
English: The maximum total daily dose is 180 mg three times a day.
Slovenian: Največji dovoljeni dnevni odmerek je 180 mg trikrat dnevno.
English: Other studies also looked at ‘switching' from an antidiabetes medicine to Trazec, and ‘adding' Trazec to other antidiabetes medicines.
Slovenian: V drugih študijah so preučevali tudi „prehod“ z zdravila za sladkorno bolezen na zdravilo Trazec ter „dodajanje“ zdravila Trazec drugemu zdravilu za sladkorno bolezen.
English: On its own, Trazec was shown to be more effective than placebo, but less effective than some antidiabetes medicines such as metformin.
Slovenian: Izkazalo se je, da je zdravilo Trazec kot samostojno zdravilo bolj učinkovito kot placebo, vendar manj učinkovito kot nekatera druga zdravila za sladkorno bolezen, kot je metformin.
English: Trazec doses might also need to be adjusted when given with some medicines used in heart conditions, to treat pain, to treat asthma, and other conditions.
Slovenian: Odmerke zdravila Trazec bo morda treba prilagoditi, če se uporabljajo istočasno z zdravili za zdravljenje bolezni srca, bolečin, astme in drugih bolezni.
English: This dose may need to be increased to a daily dose of 120 mg three times a day after one or two weeks.
Slovenian: Po enem do dveh tednih bo morda potrebno ta odmerek povečati na dnevni odmerek 120 mg trikrat dnevno.
English: The Committee for Medicinal products for Human Use (CHMP) decided that Trazec's benefits are greater than its risks for the treatment of type 2 diabetes, in combination with metformin, in patients who are not controlled despite receiving the maximum daily dose of metformin.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Trazec večje od z njim povezanih tveganj pri zdravljenju sladkorne bolezni tipa 2 v kombinaciji z metforminom pri bolnikih, pri katerih ni bil dosežen zadosten nadzor bolezni kljub prejemanju največjega dnevnega odmerka metformina.
English: Other common side effects (seen in between 1 and 10 patients in 100) are abdominal (tummy) pain, diarrhoea, dyspepsia (heartburn), and nausea (feeling sick).
Slovenian: Drugi neželeni učinki (opaženi pri 1 do 10 bolnikov izmed 100) so bolečine v trebuhu, driska, dispepsija (zgaga) in navzeja (občutek slabosti).
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood.
Slovenian: Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne tvori dovolj insulina za uravnavanje koncentracije glukoze v krvi.
English: Trazec should not be used in people who may be hypersensitive (allergic) to nateglinide or any of the other ingredients, who have type 1 diabetes, a severe liver problem, or who have diabetic ketoacidosis (a serious complication of diabetes).
Slovenian: Zdravila Trazec se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) nateglinid ali katerokoli drugo sestavino zdravila ali imajo sladkorno bolezen tipa 1 ali hude težave z jetri ali diabetično ketoacidozo (resen zaplet, povezan s sladkorno boleznijo).
English: In combination with metformin, which mainly affected fasting plasma glucose (the amount of glucose in the blood when the person has not eaten anything), the effect of Trazec on HbA1c was better than either medicine alone.
Slovenian: V kombinaciji z metforminom, ki v glavnem vpliva na koncentracijo glukoze v plazmi na tešče (količino glukoze v krvi, ko še ni bila zaužita nobena hrana), je bil učinek zdravila Trazec na HbA1c boljši od učinka katerega koli drugega zdravila, uporabljenega samostojno.
English: Trazec may in some cases cause hypoglycaemia (low blood glucose).
Slovenian: Trazec lahko v nekaterih primerih povzroči hipoglikemijo (nizko koncentracijo glukoze v krvi).
English: Trazec is used in patients who have non insulin-dependent diabetes (type 2 diabetes).
Slovenian: Trazec se uporablja pri bolnikih s sladkorno boleznijo, ki ni odvisna od insulina (sladkorna bolezen tipa 2).
English: The main studies compared Trazec to placebo (a dummy treatment), or to other medicines used in type 2 diabetes (metformin, glibenclamide or troglitazone).
Slovenian: V glavnih študijah so primerjali zdravilo Trazec s placebom (zdravilom brez zdravilne učinkovine) ali z drugimi zdravili za sladkorno bolezen tipa 2 (metforminom, gliklazidom ali troglitazonom).
English: Trazec is used together with metformin (another antidiabetes medicine) to lower blood glucose (sugar) in patients whose diabetes cannot be controlled by metformin alone.
Slovenian: Zdravilo Trazec se uporablja skupaj z metforminom (drugim zdravilom za sladkorno bolezen) za zniževanje koncentracije glukoze (sladkorja) v krvi pri bolnikih s sladkorno boleznijo, katerih sladkorno bolezen ni mogoče nadzorovati samo z metforminom.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) TRAZEC
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) TRAZEC Povzetek EPAR za javnost
English: The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
Slovenian: V študijah so merili raven snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže učinkovitost uravnavanja koncentracije glukoze v krvi.
English: Nateglinide, the active ingredient in Trazec, stimulates the pancreas to produce insulin more quickly.
Slovenian: Nateglinid, zdravilna učinkovina v zdravilu Trazec, spodbuja trebušno slinavko k hitrejši tvorbi insulina.
English: Trazec is a medicine contains the active substance nateglinide.
Slovenian: Zdravilo Trazec vsebuje zdravilno učinkovino nateglinid.
English: For the full list of all side effects reported with Trazec, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Trazec, glejte Navodilo za uporabo.
English: This helps to keep the blood glucose controlled after meals and is used to control
Slovenian: S tem se uravnavajo koncentracije glukoze v krvi po obrokih in nadzira sladkorna bolezen tipa 2.
English: The full list is available in the Package Leaflet.
Slovenian: Za celoten seznam glejte Navodilo za uporabo.
English: The marketing authorisation was renewed
Slovenian: Dovoljenje za promet z zdravilom je bilo podaljšano 3. aprila 2006.
English: This summary was last updated in 11-2011.
Slovenian: Povzetek je bil nazadnje posodobljen 11 - 2011.
English: It is available as tablets (600 mg).
Slovenian: Na voljo je v obliki tablet (600 mg).
English: It is used together with other antiviral medicines to treat adults and children aged three years or older infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Slovenian: Uporablja se skupaj z drugimi protivirusnimi zdravili pri zdravljenju odraslih in otrok, starih 3 leta ali več, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
English: The recommended dose of Efavirenz Teva for adults is 600 mg once a day.
Slovenian: Priporočeni odmerek zdravila Efavirenz Teva pri odraslih je 600 mg enkrat dnevno.
English: For full details, see the summary of product characteristics (also part of the EPAR).
Slovenian: Za podrobnejše informacije glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
English: The full EPAR for Efavirenz Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Efavirenz Teva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Efavirenz Teva on 9 January 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Efavirenz Teva, veljavno po vsej Evropski uniji, odobrila dne 09. januarja 2012.
English: Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
Slovenian: Dve zdravili sta biološko enakovredni, kadar v telesu dosegata enake ravni zdravilne učinkovine.
English: Efavirenz Teva does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Slovenian: Zdravilo Efavirenz Teva ne ozdravi okužbe s HIV ali aidsa, vendar pa lahko upočasni slabšanje imunskega sistema in razvoj okužb in bolezni, povezanih z aidsom.
English: It is recommended that Efavirenz Teva be taken on an empty stomach and without food, preferably at bedtime.
Slovenian: Priporočljivo je, da se zdravilo Efavirenz Teva jemlje na prazen želodec in brez hrane, po možnosti pred spanjem.
English: For more information about treatment with Efavirenz Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Efavirenz Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: It blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells in the body and make more viruses.
Slovenian: Ta zavira delovanje reverzne transkriptaze, encima, ki ga tvori virus HIV in ki omogoča okužbo celic v telesu ter nastajanje novih virusov.
English: Efavirenz Teva tablets are not suitable for children weighing less than 40 kg. Efavirenz-containing capsules are available for these patients.
Slovenian: Tablete zdravila Efavirenz Teva niso primerne za otroke, ki tehtajo manj kot 40 kg. Za te bolnike so na voljo kapsule, ki vsebujejo efavirenz.
English: Patients taking rifampicin (an antibiotic) may need to take a higher dose of Efavirenz Teva.
Slovenian: Bolniki, ki jemljejo rifampicin (antibiotike) bodo morda potrebovali višji odmerek zdravila Efavirenz Teva.
English: EPAR summary for the public efavirenz
Slovenian: Povzetek EPAR za javnost efavirenz
English: What are the benefits and risks of Efavirenz Teva?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Efavirenz Teva?
English: This means that Efavirenz Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Sustiva.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Sustiva.
English: Therefore, the CHMP's view was that, as for Sustiva, the benefit outweighs the identified risk.
Slovenian: Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Sustiva, odtehtajo znana tveganja.
English: Because Efavirenz Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Efavirenz Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: This is a summary of the European public assessment report (EPAR) for Efavirenz Teva.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Efavirenz Teva.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Efavirenz Teva.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Efavirenz Teva, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: The dose of Efavirenz Teva needs to be reduced in patients taking voriconazole (used to treat fungal infections).
Slovenian: Odmerek zdravila Efavirenz Teva je treba zmanjšati pri bolnikih, ki jemljejo vorikonazol (ki se uporablja pri zdravljenju glivičnih obolenj).
English: By blocking this enzyme, Efavirenz Teva, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Slovenian: Zdravilo Efavirenz Teva, ki se jemlje skupaj z drugimi protivirusnimi zdravili, z zaviranjem tega encima zmanjša koncentracijo virusa HIV v krvi in jo ohranja na nizki ravni.
English: Efavirenz Teva must be given in combination with other antiviral medicines.
Slovenian: Zdravilo Efavirenz Teva je treba dajati v kombinaciji z drugimi protivirusnimi zdravili.
English: Because Efavirenz Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Sustiva.
Slovenian: Ker je zdravilo Efavirenz Teva generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Sustiva.
English: The active substance in Efavirenz Teva, efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Slovenian: Zdravilna učinkovina zdravila Efavirenz Teva, efavirenz, je nenukleozidni zaviralec reverzne transkriptaze (NNRTI).
English: The CHMP concluded that, in accordance with EU requirements, Efavirenz Teva has been shown to have comparable quality and to be bioequivalent to Sustiva.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Efavirenz Teva primerljivo raven kakovosti kot zdravilo Sustiva ter da mu je biološko enakovredno.
English: Treatment with Efavirenz Teva should be started by a doctor who has experience in the management of HIV infection.
Slovenian: Zdravljenje z zdravilom Efavirenz Teva lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
English: The Committee recommended that Efavirenz Teva be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Efavirenz Teva odobri dovoljenje za promet.
English: Efavirenz Teva is a ‘generic medicine'.
Slovenian: Efavirenz Teva je „generično zdravilo“.
English: Efavirenz Teva is a medicine that contains the active substance efavirenz.
Slovenian: Efavirenz Teva je zdravilo, ki vsebuje zdravilno učinkovino efavirenz.
English: Other information about Efavirenz Teva
Slovenian: Druge informacije o zdravilu Efavirenz Teva:
English: Efavirenz Teva is an antiviral medicine.
Slovenian: Efavirenz Teva je protivirusno zdravilo.
English: Why has Efavirenz Teva been approved?
Slovenian: Zakaj je bilo zdravilo Efavirenz Teva odobreno?
English: How has Efavirenz Teva been studied?
Slovenian: Kako je bilo zdravilo Efavirenz Teva raziskano?
English: What is Efavirenz Teva?
Slovenian: Kaj je zdravilo Efavirenz Teva?
English: How is Efavirenz Teva used?
Slovenian: Kako se zdravilo Efavirenz Teva uporablja?
English: What is Efavirenz Teva used for?
Slovenian: Za kaj se zdravilo Efavirenz Teva uporablja?
English: How does Efavirenz Teva work?
Slovenian: Kako zdravilo Efavirenz Teva deluje?
English: Need help?
Slovenian: Potrebujete pomoč?
English: The average follow-up was approximately two years.
Slovenian: Povprečni čas spremljanja je bil približno dve leti.
English: These are both normal and do not need to be removed.
Slovenian: Oba sta normalna in vam ju ni treba odstraniti.
English: Date of first authorisation: 1 October 2009 Date of latest renewal: 19 June 2014
Slovenian: Datum prve odobritve: 1. oktober 2009 Datum zadnjega podaljšanja: 19. junij 2014
English: Some of these patients died.
Slovenian: Nekateri od teh bolnikov so umrli.
English: The significance of this finding is unknown.
Slovenian: Pomen tega izsledka ni znan.
English: 24 months
Slovenian: 24 mesecev
English: Keep holding, then lift
Slovenian: Držite še naprej, nato dvignite
English: You may also see one or more air bubbles.
Slovenian: Morda boste videli tudi enega ali več zračnih mehurčkov.
English: Patient's Name: _____________________ Doctor's Name: _____________________ Doctor's Phone: _____________________
Slovenian: Ime bolnika: _____________________ Ime zdravnika: _____________________ Tel. št. zdravnika: _____________________
English: Your injection is now complete!
Slovenian: Vaše injiciranje je sedaj dokončano!
English: • You will also notice an air bubble, which is normal.
Slovenian: • Lahko boste opazili tudi zračni mehurček, kar je normalno.
English: • Again, all sites mentioned can be used regardless of your body type or size.
Slovenian: • Uporabljajo se lahko vsa omenjena mesta, ne glede na vaš telesni tip ali velikost.
English: You may or may not feel a needle prick at this time.
Slovenian: V tem času lahko ali pa tudi ne čutite pika igle.
English: Most of these patients were adolescent or young adult males.
Slovenian: Večina teh bolnikov je bila mladostnikov ali mladih odraslih moškega spola.
English: Get the rest of your equipment ready
Slovenian: Pripravite si ostale potrebščine
English: Some orange will still be showing.
Slovenian: Nekaj oranžne bo še vedno vidne.
English: This type of cancer has usually resulted in death.
Slovenian: Ta vrsta raka je bila ponavadi smrtna.
English: • Certain vaccinations may cause infections.
Slovenian: • Določena cepljenja lahko povzročijo okužbe.
English: This usually takes about 3-6 seconds, but it may take up to 15 seconds for you to hear the second ‘click' sound.
Slovenian: Običajno traja približno 3 do 6 sekund, lahko pa tudi do 15 sekund, da zaslišite drugi ‘klik'.
English: Your doctor will tell you the correct dose to use.
Slovenian: Zdravnik vam bo povedal, kakšen je pravilni odmerek, ki ga morate uporabljati.
English: *Removing air bubbles helps make sure the right dose is given.
Slovenian: *Odstranitev zračnih mehurčkov pomaga zagotoviti, da dobite pravi odmerek.
English: Do not warm any other way.
Slovenian: Zdravila ne segrevajte na kakršen koli drug način.
English: These medicines are used for the treatment of rheumatic diseases.
Slovenian: Ta zdravila se uporabljajo za zdravljenje revmatičnih bolezni.
English: • The yellow indicator will fill about half of the viewing window.
Slovenian: • Rumeni kazalnik bo zapolnil približno polovico okenca.
English: Consequently, these infants may be at increased risk of infection.
Slovenian: Posledično lahko pri teh dojenčkih obstaja večje tveganje za okužbe.
English: • Difficulty sleeping
Slovenian: • težave s spanjem,
English: You will find detailed “Instructions for Use” at the end of this leaflet.
Slovenian: Podrobna "Navodila za uporabo" najdete na koncu tega navodila.
English: • Children weighing at least 40 kg:
Slovenian: • Otroci, ki tehatajo vsaj 40 kg:
English: • Some of these reactions may be serious or, rarely, life-threatening.
Slovenian: • Nekatere od teh reakcij so lahko resne ali, v redkih primerih, življenjsko nevarne.
English: You will need these supplies:
Slovenian: Potrebovali boste naslednje:
English: This instruction guide does not take the place of talking with your doctor about your medical condition or your treatment.
Slovenian: Ta navodila niso nadomestilo za pogovor z zdravnikom o vašem zdravstvenem stanju ali vašem zdravljenju.
English: • You will choose from 2 injection methods.
Slovenian: • Izberite med dvema načinoma injiciranja.
English: In addition, some previous infections may reappear.
Slovenian: Poleg tega se lahko ponovno pojavijo nekatere prejšnje okužbe.
English: Side effects may appear up to several months after the last injection.
Slovenian: Neželeni učinki se lahko pojavijo do več mesecev po zadnji injekciji.
English: Your doctor may decide to stop treatment.
Slovenian: Zdravnik se bo morda odločil, da vaše zdravljenje prekine.
English: Rare: Lupus-like syndrome
Slovenian: Redki: lupusu podoben sindrom
English: For paediatric patients < 40 kg
Slovenian: Za pediatrične bolnike < 40 kg